ArticleFrontiers in aging neuroscience2026
Association between the triglyceride-glucose index and disease severity in non-diabetic Parkinson's disease patients.
Article in Frontiers in aging neuroscience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The triglyceride-glucose (TyG) index is a well-established biomarker of insulin resistance (IR) in non-diabetic populations, serving as a reliable indicator of metabolic health across diverse demographic groups. However, to date, few studies have explored the association between IR-as measured by the TyG index and disease severity in non-diabetic patients with Parkinson's disease (PD). Methods: PD Patients were recruited from the Department of Neurology at The First Affiliated Hospital of Kunming Medical University between 2020 and 2025. Disease severity in Parkinson's disease (PD) was assessed using the Hoehn-Yahr (HY) staging system, where stages I-II correspond to the early phase and stages beyond II indicate intermediate-to-advanced progression. The study compared TyG index differences between these groups. Spearman correlation analysis evaluated associations between individual variables and disease severity in non-diabetic PD patients. Logistic regression analysis calculated odds ratios (ORs) with 95% confidence intervals (CIs), with additional adjustment for PD-specific confounders (disease duration, age at onset, LEDD) and nutritional/metabolic markers (UA, TC, LDL, HDL, creatinine). Restricted cubic spline (RCS) analysis further examined the relationship with disease severity. Results: A total of 458 non-diabetic patients with Parkinson's disease (PD) were enrolled. The TyG index was significantly lower in the intermediate-to-advanced stage group compared to the early-stage group (Z = -2.257, Conclusion: In non-diabetic PD patients, a lower TyG index was associated with greater disease severity in more advanced HY stages, but this relationship is not independent after full adjustment. Moreover, reverse causality could not be ruled out and requires validation in future prospective studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.